Scientific deep-dive
Why the Appetite Comes Back
Weight loss slows and appetite for particular foods creeps back. A Science study found a specific brain circuit doing exactly that, in mice, whose neurons can be switched off with light.
Weight loss on these drugs slows, and many people describe their appetite for particular foods creeping back while still taking them. A study in Science found a specific brain circuit doing exactly that. Mice on repeated semaglutide recovered both their taste for palatable food and the dopamine activity underlying it.[1] Everything here is in mice. It is a mechanism worth understanding, not a finding about you. In people, a small trial found semaglutide sharpened taste recognition while dimming the brain’s response to pictures of food.
What they found
Hedonic eating is eating for pleasure rather than need, like the second helping of something delicious when hunger is already gone. The researchers traced a pathway running from a region near the locus coeruleus to the ventral tegmental area, and found that dopamine neurons there encode palatability: their activity tracks how good the food is, and driving them up or down raises or lowers how much of it an animal eats.
Semaglutide suppressed the responsiveness of those neurons during eating. That is a plausible mechanism for the drug reducing pleasure-driven consumption specifically, rather than only signaling fullness.
Then, with repeated treatment, the appetite came back, and so did the neurons.
That recovery is the finding. Over continued semaglutide, mice regained both their consumption of palatable food and the dopamine activity that accompanies it. The suppression was not permanent.
The step that makes it a causal claim
Two things recovering together is a correlation. The researchers then inhibited those dopamine neurons at the moment of eating, and the recovery of appetite was reversed.
That is what separates this from an observation. If switching the circuit off undoes the effect, the circuit is doing the work rather than merely accompanying it. Their conclusion is that hedonic eating activates these neurons, which then sustain further eating. The result is a self-reinforcing loop that opposes the appetite reduction the drug produces.
What it does and does not explain
Weight loss curves in every trial of this class flatten over time, and the flattening is usually attributed to metabolic adaptation, in which the body defends its weight by lowering energy expenditure. That is real and well documented. This work proposes something running alongside it: a reward pathway recovering its influence over food choice.
It would fit what people report. The return described is often not general hunger but a specific pull toward particular foods, which is what a palatability-encoding circuit would produce rather than what a broad hunger signal would.
It does not explain everything, and it does not establish anything in humans. The equivalent experiment cannot be run in people, so testing the idea here means indirect evidence: imaging, food-choice measures, and drugs that act on the same pathway. Very little of that has been done.
Why there is no advice at the end of this
Some articles end with something to do. This one does not, and inventing a takeaway would be a mistake. Nobody can inhibit their own ventral tegmental dopamine neurons, and no drug currently prescribed does it deliberately.
What it offers is a frame. If appetite for particular foods returns during treatment, that is a documented phenomenon with a candidate biological mechanism, not a personal failure of resolve and not proof the treatment has quit. The evidence on what happens to weight over the long run is in the semaglutide timeline, and what patients themselves call the effect is in food noise, what it is.
Frequently Asked Questions
References
- 1.Zhu Z, Gong R, Rodriguez V, et al. Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety Science. 2025. PMID: 40146831.
Compare the sellers
Related research
The Thing That Makes Regain Inevitable
Metabolic adaptation is the leading explanation for why weight loss plateaus and returns. A study asked whether tirzepatide interrupts it. In mice it did; in people it did not.
7 min read
Stretching Doses to Save Money
At list prices above a thousand dollars a month, people stretch these drugs. Two papers argue fortnightly dosing keeps most of the weight loss, on a mathematical model and a case series of two patients.
8 min read
Can You Lower the Dose and Keep the Weight Off?
Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25%, and to 67% on placebo.
6 min read
The Cardiovascular Cost of Stopping
A review argues that weight and blood sugar fluctuation are themselves cardiovascular risk factors, and that these drugs do not stabilize arteries the way statins do. It also says few data exist on hard outcomes after stopping.
5 min read
What a Plateau Actually Means
Nine in ten people had plateaued by week 72. Because of how the researchers defined a plateau, you can be counted as plateaued while still losing about 16% of your body weight a year.
6 min read
Stopping as a Clinical Transition
A review argues discontinuation is a high-risk clinical transition, and reports an association with later heart disease that another review says barely exists as data. Both are describing the same thin literature.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
MyDrHank
An oral route if you will not self-inject
From $171/mo, prepaid
Get started →YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →